CoQ10 and Omega-3 as Adjuncts to Periodontal Therapy, TAC of Saliva.
Conditions: Periodontal Diseases Interventions: Drug: Receive Coq10 gel; Drug: Non-Medicare Drugs Sponsors: Amirhossein Farahmand Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Evaluation of Functionality of Amputees According to the Medicare Functional K Classification System
Conditions: Amputation; Amputation; Traumatic, Leg, Lower Interventions: Other: Lower extremity unilateral amputee Sponsors: Medipol University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
Conditions: Diffuse Large B-cell Lymphoma Sponsors: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Conditions: Breast Cancer Interventions: Drug: Palbociclib; Drug: Aromatase Inhibitor Sponsors: Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
Assessment of implementation methods in sepsis: study protocol for a cluster-randomized hybrid type 2 trial
This study will be entirely conducted in the Emergency Department at 18 sites. A seco ndary aim is to identify clinical sepsis phenotypes and their impact on treatment outcomes.DiscussionThis cluster-randomized trial, employing implementation science methodology, is timely and important to the field. The hybrid effectiveness-implementation design is likely to have an impact on clinical practice in sepsis management by providing a rigorous evaluation of the 1- and 3-h bundles.FundingNHLBI R01HL162954.Trial registrationClinicalTrials.gov NCT05491941. Registered on August 8, 2022. (Source: Trials)
Source: Trials - September 29, 2023 Category: Research Source Type: clinical trials
Medicare Anti-A β mAb Coverage With Evidence Development (CED) Study
Conditions: Mild Alzheimer's Disease; Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease Intervention: Drug: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Sponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Medicare Anti-A β mAb Coverage With Evidence Development (CED) Study
Conditions: Mild Alzheimer ' s Disease; Mild Cognitive Impairment (MCI) Due to Alzheimer ' s Disease Interventions: Drug: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer ' s Disease Sponsors: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Increasing the Feasibility, Impact, and Equity of the Medicare Annual Wellness Visit (AWV)
Condition: Preventive Health Services Intervention: Behavioral: Medicare AWV Practice Redesign Toolkit Sponsors: University of California, Los Angeles; DARTNet; American Academy of Family Physicians National Research Network; Case Western Reserve University; The MetroHealth System Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2023 Category: Research Source Type: clinical trials
